FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116788716> ?p ?o ?g. }

• W2116788716 endingPage "1687" @default.
• W2116788716 startingPage "1680" @default.
• W2116788716 abstract "BackgroundThis phase III open-label trial investigated the efficacy of nilotinib in patients with advanced gastrointestinal stromal tumors following prior imatinib and sunitinib failure.Patients and methodsPatients were randomized 2 : 1 to nilotinib 400 mg b.i.d. or best supportive care (BSC; BSC without tyrosine kinase inhibitor, BSC + imatinib, or BSC + sunitinib). Primary efficacy end point was progression-free survival (PFS) based on blinded central radiology review (CRR). Patients progressing on BSC could cross over to nilotinib.ResultsTwo hundred and forty-eight patients enrolled. Median PFS was similar between arms (nilotinib 109 days, BSC 111 days; P = 0.56). Local investigator-based intent-to-treat (ITT) analysis showed a significantly longer median PFS with nilotinib (119 versus 70 days; P = 0.0007). A trend in longer median overall survival (OS) was noted with nilotinib (332 versus 280 days; P = 0.29). Post hoc subset analyses in patients with progression and only one prior regimen each of imatinib and sunitinib revealed a significant difference in median OS of >4 months in favor of nilotinib (405 versus 280 days; P = 0.02). Nilotinib was well tolerated.ConclusionIn the ITT analysis, no significant difference in PFS was observed between treatment arms based on CRR. In the post hoc subset analyses, nilotinib provided significantly longer median OS." @default.
• W2116788716 created "2016-06-24" @default.
• W2116788716 creator A5003882278 @default.
• W2116788716 creator A5007466199 @default.
• W2116788716 creator A5010607855 @default.
• W2116788716 creator A5020515172 @default.
• W2116788716 creator A5025935523 @default.
• W2116788716 creator A5042202815 @default.
• W2116788716 creator A5048170384 @default.
• W2116788716 creator A5060580923 @default.
• W2116788716 creator A5068927415 @default.
• W2116788716 creator A5074975947 @default.
• W2116788716 creator A5091177812 @default.
• W2116788716 date "2012-07-01" @default.
• W2116788716 modified "2023-10-16" @default.
• W2116788716 title "Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib" @default.
• W2116788716 cites W1967920366 @default.
• W2116788716 cites W1975595356 @default.
• W2116788716 cites W1987005540 @default.
• W2116788716 cites W2015015957 @default.
• W2116788716 cites W2020103507 @default.
• W2116788716 cites W2035910722 @default.
• W2116788716 cites W2052471444 @default.
• W2116788716 cites W2054251966 @default.
• W2116788716 cites W2061860992 @default.
• W2116788716 cites W2063299240 @default.
• W2116788716 cites W2098785293 @default.
• W2116788716 cites W2107464631 @default.
• W2116788716 cites W2115504770 @default.
• W2116788716 cites W2115811601 @default.
• W2116788716 cites W2117624277 @default.
• W2116788716 cites W2119505091 @default.
• W2116788716 cites W2123859714 @default.
• W2116788716 cites W2124525681 @default.
• W2116788716 cites W2125317841 @default.
• W2116788716 cites W2129788326 @default.
• W2116788716 cites W2129931005 @default.
• W2116788716 cites W2139248078 @default.
• W2116788716 cites W2139511378 @default.
• W2116788716 cites W2148738557 @default.
• W2116788716 cites W2158933399 @default.
• W2116788716 cites W2169363650 @default.
• W2116788716 cites W2170783473 @default.
• W2116788716 cites W2314511842 @default.
• W2116788716 cites W4238208852 @default.
• W2116788716 doi "https://doi.org/10.1093/annonc/mdr598" @default.
• W2116788716 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22357255" @default.
• W2116788716 hasPublicationYear "2012" @default.
• W2116788716 type Work @default.
• W2116788716 sameAs 2116788716 @default.
• W2116788716 citedByCount "120" @default.
• W2116788716 countsByYear W21167887162012 @default.
• W2116788716 countsByYear W21167887162013 @default.
• W2116788716 countsByYear W21167887162014 @default.
• W2116788716 countsByYear W21167887162015 @default.
• W2116788716 countsByYear W21167887162016 @default.
• W2116788716 countsByYear W21167887162017 @default.
• W2116788716 countsByYear W21167887162018 @default.
• W2116788716 countsByYear W21167887162019 @default.
• W2116788716 countsByYear W21167887162020 @default.
• W2116788716 countsByYear W21167887162021 @default.
• W2116788716 countsByYear W21167887162022 @default.
• W2116788716 countsByYear W21167887162023 @default.
• W2116788716 crossrefType "journal-article" @default.
• W2116788716 hasAuthorship W2116788716A5003882278 @default.
• W2116788716 hasAuthorship W2116788716A5007466199 @default.
• W2116788716 hasAuthorship W2116788716A5010607855 @default.
• W2116788716 hasAuthorship W2116788716A5020515172 @default.
• W2116788716 hasAuthorship W2116788716A5025935523 @default.
• W2116788716 hasAuthorship W2116788716A5042202815 @default.
• W2116788716 hasAuthorship W2116788716A5048170384 @default.
• W2116788716 hasAuthorship W2116788716A5060580923 @default.
• W2116788716 hasAuthorship W2116788716A5068927415 @default.
• W2116788716 hasAuthorship W2116788716A5074975947 @default.
• W2116788716 hasAuthorship W2116788716A5091177812 @default.
• W2116788716 hasBestOaLocation W21167887161 @default.
• W2116788716 hasConcept C121608353 @default.
• W2116788716 hasConcept C126322002 @default.
• W2116788716 hasConcept C143998085 @default.
• W2116788716 hasConcept C203092338 @default.
• W2116788716 hasConcept C2777413986 @default.
• W2116788716 hasConcept C2777583451 @default.
• W2116788716 hasConcept C2778729363 @default.
• W2116788716 hasConcept C2778820342 @default.
• W2116788716 hasConcept C2779490328 @default.
• W2116788716 hasConcept C2780739268 @default.
• W2116788716 hasConcept C3019892230 @default.
• W2116788716 hasConcept C3019894029 @default.
• W2116788716 hasConcept C535046627 @default.
• W2116788716 hasConcept C67761136 @default.
• W2116788716 hasConcept C71924100 @default.
• W2116788716 hasConcept C90924648 @default.
• W2116788716 hasConceptScore W2116788716C121608353 @default.
• W2116788716 hasConceptScore W2116788716C126322002 @default.
• W2116788716 hasConceptScore W2116788716C143998085 @default.
• W2116788716 hasConceptScore W2116788716C203092338 @default.
• W2116788716 hasConceptScore W2116788716C2777413986 @default.
• W2116788716 hasConceptScore W2116788716C2777583451 @default.

• next